Study on the Safety and Effectiveness of Guanxinning Tablets in Intensive Therapy for Patients with Acute Coronary Syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005434

Enrollment

Unknown

Registered

2021-12-21

Start date

2021-12-21

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

Conventional treatment group:Conventional treatment

Guanxinning tablet loading treatment group:The loading treatment group was given intensive treatment with Guanxinning tablets (3 times a day, 8 tablets each time) for 14 days. On the 15th to 30th days

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnostic criteria for acute myocardial infarction: elevated cardiac troponin (cTn), at least once the value is higher than the upper limit of 99% of the reference value, and at least one of the following: ? symptoms of acute myocardial ischemia; ? new ischemia ECG changes; ? pathological Q waves; (4) imaging evidence of newly viable myocardium loss or new segmental ventricular wall motion abnormalities. If ECG manifests as ST-segment elevation in two or more adjacent leads, new left bundle branch block or hyperacute T wave changes, it is defined as SETMI. If there is no ST-segment elevation on the ECG at the time of consultation, it is defined as NSTEMI. Diagnostic criteria for unstable angina (UA): ?Including first-onset exertional angina, worsening exertional angina, resting angina, and variant angina; ?ischemic chest pain time =30min; ?The ECG showed ST-segment level or Decline depression = 1 mm or ST segment elevation (limb leads = 1 mm, chest leads = 2 mm), after the onset, the ST segment returns to the level before the onset; ? no changes in blood myocardial necrosis markers.

Exclusion criteria

Exclusion criteria: ?Age 180/110mmHg) ); ? pregnant women, breast-feeding women; ? allergic constitution, or food allergies to multiple drugs; (8) patients who have participated in clinical trials of other drugs within 1 month.

Design outcomes

Primary

Measure	Time frame
Antiplatelet aggregation rate;Inflammation-related factors (TNF-a, IL-1, IL-6, IL-10);Hypersensitive-c-reactive-protein;Oxidative stress indicators (SOD, ROS);Troponin T;Nitric Oxide;Electrocardiogram;Creatine Kinase, MB Form;	—

Countries

China

Contacts

Public ContactXu Yizhou

qqyzxu@hotmail.com13357109696

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026